When the FDA approved esketamine nasal spray for treatment-resistant depression in 2019, it marked a turning point in psychiatric pharmacology. For the first time in decades, a genuinely new class of antidepressant had received regulatory approval, and it worked faster and through a different mechanism than anything that had come before. Five years on, Spravato has become an established part of specialist psychiatric practice, and access in major cities like New York has grown considerably.
Yet many patients who might benefit from it are still unfamiliar with what it involves, how it differs from other forms of ketamine treatment, and what finding a provider actually entails. This article addresses all of that.
What Is Esketamine and How Does It Work?
Esketamine is the S-enantiomer of ketamine, meaning it is one of two mirror-image forms of the ketamine molecule. It was developed specifically for intranasal delivery and was studied in large clinical trials for treatment-resistant depression before receiving FDA approval under the brand name Spravato.
Like all forms of ketamine, esketamine works primarily through the glutamate system, acting as an NMDA receptor antagonist. This mechanism produces rapid antidepressant effects through a pathway that is fundamentally different from conventional antidepressants, which target the serotonin, norepinephrine, and dopamine systems. The result is a speed of action that conventional antidepressants cannot match, with meaningful reductions in depressive symptoms often apparent within hours to days of the first dose.
The clinical evidence behind Spravato is extensive. Multiple randomised controlled trials demonstrated its efficacy in treatment-resistant depression, and the FDA has since extended its approval to cover major depressive disorder with acute suicidal ideation or behaviour, reflecting its particular value for patients in acute psychiatric crisis.
How Spravato Differs From IV Ketamine
Patients researching ketamine-based treatments often encounter both Spravato and intravenous ketamine infusion as options and want to understand the difference. The active compound is closely related in both cases, but the delivery method, regulatory status, and practical experience differ in important ways.
Spravato is self-administered as a nasal spray under the direct supervision of a healthcare provider in a certified healthcare facility. The patient administers the spray themselves while in the clinic, then remains under observation for at least two hours to monitor for potential side effects, including dissociation and sedation, before being cleared to leave.
IV ketamine infusion involves the drug being delivered directly into the bloodstream through an intravenous line over approximately 40 to 60 minutes. This produces a different pharmacokinetic profile and a somewhat different subjective experience, and many clinicians consider IV infusion to produce a more reliably dissociative experience during administration.
The most clinically significant difference is regulatory. Spravato is FDA-approved specifically for depression, which means it has a defined evidence base, a standardised dosing protocol, and established insurance coverage for eligible patients. IV ketamine is used off-label for psychiatric indications, which affects both reimbursement and the degree of formal guidance available for its clinical use.
Finding Spravato Treatment Near You
For patients considering Village TMS Spravato treatment, availability has grown considerably since the initial FDA approval. Spravato must be administered in a certified healthcare setting, meaning patients cannot take it at home, but the number of certified providers has expanded significantly and waiting times at established clinics are generally manageable.
A standard Spravato programme begins with an induction phase during which treatment is administered twice weekly for four weeks. This is followed by a maintenance phase with once-weekly dosing for a further four weeks, then fortnightly dosing for ongoing maintenance. The schedule is more demanding than a weekly therapy appointment but considerably less disruptive than inpatient treatment, and most patients manage it alongside work and family life.
According to the FDA, Spravato must be used in conjunction with an oral antidepressant rather than as a standalone treatment, and it must be administered under direct healthcare provider supervision. These requirements are part of the treatment’s Risk Evaluation and Mitigation Strategy, which exists to manage the risks of dissociation, sedation, and misuse that are associated with ketamine-based treatments.
Esketamine Treatment Near You
For patients exploring Esketamine near me options in New York City, the city’s concentration of specialist psychiatric clinics means that access is genuinely good. The most important factors in choosing a provider are the same as for any specialist psychiatric treatment: active clinical oversight, thorough pre-treatment evaluation, and attentive monitoring throughout.
Because Spravato requires on-site administration and post-dose observation, the practical experience of treatment is somewhat different from taking an oral medication. Patients typically spend two to four hours at the clinic on treatment days. Many patients find they can read, listen to music, or simply rest during the observation period, and clinic environments at quality providers are designed to be calm and comfortable.
The dissociative effects that some patients experience during and after dosing typically resolve during the observation period. These effects vary considerably between patients: some find them mild and barely noticeable, while others experience more pronounced alterations in perception. Either way, patients are not permitted to drive or engage in activities requiring full alertness until the following day.
Who Is a Good Candidate for Spravato?
Spravato is indicated for adults with treatment-resistant depression who have not achieved adequate improvement from at least two different oral antidepressants taken at adequate doses for adequate durations. It is also indicated for adults with major depressive disorder experiencing acute suicidal ideation or behaviour.
Patients with a history of psychosis, uncontrolled hypertension, certain vascular conditions, or active substance use disorder may not be appropriate candidates, and a thorough medical and psychiatric evaluation is essential before beginning treatment. The evaluation will also establish a baseline against which treatment response can be measured over time.
Insurance coverage for Spravato is available through most major commercial plans and through Medicare and Medicaid for patients who meet clinical criteria, making it considerably more financially accessible than IV ketamine for many patients.
Moving Forward
If you have been living with depression that has not responded to antidepressant medication, Spravato and esketamine treatment represent a well-evidenced, FDA-approved option with genuine clinical support behind them. Village TMS in New York City offers Spravato treatment within a comprehensive psychiatric practice, delivered by a team that understands both the potential and the practicalities of this treatment.
Contact Village TMS today to find out whether Spravato is appropriate for your situation and to begin the process of accessing care that could genuinely change the trajectory of your treatment.